Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
After endometrial cancer surgery, there is a risk that the cancer will come back. Combining a shorter course of radiation treatment with chemotherapy may decrease the chance of endometrial cancer recurring.
In this study, researchers are assessing the safety and effectiveness of using the drug ruxolitinib in patients with T-cell lymphoma or natural killer (NK)-cell lymphoma that has come back or continued to grow despite prior treatment. Ruxolitinib is already approved for treating a bone marrow disease called myelofibrosis. It works by inhibiting a protein called JAK, which works with another protein called STAT to promote the growth of many T-cell and NK-cell lymphomas. By blocking JAK, ruxolitinib may cause lymphomas to shrink.
Researchers want to find the best dose of AZD0305 to use in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment. AZD0305 is given intravenously (by vein).
Researchers in this study are comparing two different treatments for Hodgkin lymphoma (HL). The people in this study have early-stage (stage 1 or 2) HL that has not yet been treated.
Researchers want to find the best dose of lorlatinib to give with ramucirumab in people with lung cancer. They are also seeing how well this drug combination works. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread). In addition, their cancers have a fusion involving the ALK gene. A fusion gene is made when parts of two different genes in your body join together.
In this study, researchers want to see how well a personalized vaccine works for people with pancreatic cancer. The people in this study have pancreatic cancer that can be taken out with surgery. The vaccine is called autogene cevumeran. It is an "mRNA vaccine," made in a way similar to the vaccines used to prevent COVID. It will be given in combination with a drug called atezolizumab and a chemotherapy treatment called mFOLFIRINOX.
In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.
The purpose of this study is to assess the safety and effectiveness of the investigational drug MORAb-202 in people with endometrial or ovarian cancer. MORAb-202 targets a protein called FRA on cancer cells and delivers eribulin (a chemotherapy drug) directly to these cells, which may slow or stop cancer growth. MORAb-202 is given intravenously (by vein).
Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.
Brentuximab vedotin (BV) plus chemotherapy with the drugs cyclophosphamide, doxorubicin, and prednisone (CHP) is a standard treatment for T-cell lymphomas that make the CD30 protein. Researchers want to see if BV with an enhanced chemotherapy regimen that includes etoposide works better in people with T-cell lymphomas.
